spacer
home > ebr > spring 2007 > the life science love affair with interim management
PUBLICATIONS
European Biopharmaceutical Review

The Life Science Love Affair with Interim Management



The life sciences industry consistently ranks among the top three users of interim managers, according to the latest figures from Ipsos MORI for the industry body, the Interim Management Association. It’s a significant development over just a few years, as Perry Evans, of RSA explains

Since it arrived in the UK in the mid-1980s, the interim management market has been growing steadily and the industry is now thought to be worth £1 billion a year. It has taken longer for pharma and biotech industries to realise the benefits of interim management than some other sectors. However, human resources managers are now embracing flexible ways to add value to their businesses.

There are also corresponding changes in the ‘typical’ profile of interim managers – the age range has dropped significantly and we are seeing more successful professionals in their 30s and 40s making a career out of short-term interim assignments. Better understanding of what interim management is and how it works has made the hiring of readily available hands-on experts a more appealing, cost-effective option. In life sciences, interim opportunities are now available in almost every area, from discovery through to sales and marketing.

Interim management is the answer to a short-term resourcing need at senior or specialist levels. It places an experienced professional in an operational role on a short-term assignment within a company. Assignments typically last six to nine months, and the specific skills and experience required can range from leadership, managerial, functional, or a combination of each at multiple levels. Interims operate independently as limited companies and are paid a daily fee. For clients, this means that they only pay for the time the interim spends there, and when the job is finished, the interim leaves. They can add value in a variety of ways, but two key factors usually apply.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Perry Evans is the Manager of RSA Interims and has a BA in Business Studies. He is a British Psychological Society approved test administrator and is trained in conducting competency-based interviews. Perry has 20 years’ recruitment experience in a wide range of sectors, including medical, healthcare, automotive, telecoms and FMCG. He has experience in key account management, international recruitment and managing volume recruitment campaigns.
spacer
Perry Evans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm accelerates strategy to broaden service offering into commercial manufacturing

MedPharm Ltd, a leading contract provider of topical and transdermal product design and development services, has announced two new appointments to its Board to support plans to grow its commercial manufacturing services.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement